Masking Effect in the Process of Signal Detection of Adverse Drug Reaction

Abstract

Abstract: Routine adverse drug reaction signal detection Methods based on disproportionality analysis are playing important role in the process of adverse drug reaction surveillance. However, these Methods have their own drawbacks in the accuracy for signal detection and could not solve some problems which include masking effect. These problems should be solved through new analysis strategy. In this article, we present the impact of masking effect on the signal detection and introduce the latest research on the identification and elimination of masking effect.

Key words: masking effect, adverse drug reaction, signal detection

CLC Number:

R954

YE Xiao-fei, CHENG Gang, GUO Xiao-jing, XU Jin-fang, HE Jia . Masking Effect in the Process of Signal Detection of Adverse Drug Reaction [J]. Chinese Journal of Pharmacovigilance, 2013, 10(1): 33-35.

References

[1] NorénG N, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery [J]. Statistical Methods in Medical Research,2011 Jun 29.[Epub ahead of print].
[2] Eugene P. van Puijenbroek, Andrew Bate, Hubert G. M. Leufkens, et al.A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions[J].Pharmacoepidemiology and drug safety, 2002, 11:3-10.
[3] Norén GN, Sundberg R, Bate A,et al.A statistical methodology for drug-drug interaction surveillance [J]. Stat Med, 2008,27 (16): 3057-70.
[4] Strandell J, Caster O, Bate A, et al. Reporting patterns indicative of adverse drug interactions-a systematic evaluation [J]. Drug Saf 2011,34(3):253-266.
[5] Almenoff J, TonningJ M, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance [J]. Drug Saf,2005,28 (11): 981-1007.
[6] Wang H W, HochbergA M, Pearson R K, et al. An experimental investigation of masking in the US FDA adverse event reporting system database[J]. Drug Saf, 2010, 33:1117-1133.
[7] 周静雯,苏雅茹.世界卫生组织药物词典及其应用[J].药物流行病学杂志, 2011,9:478-483.
[8] Pariente A, Didailler M, Avillach P,et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases[J]. Pharmacoepidemiol Drug Saf, 2010,19:1166-1171.
[9] Ziad Zeinoun, Harry Seifert, Thomas Verstraeten. Quantitative signal detection for vaccines Effect of stratification, background and masking on GlaxoSmithKline's spontaneous reports database [J]. Human Vaccines, 2009,5(9):599-607.
[10] Caster O, Norén GN, Madigan D, et al. Large-Scale Regression-Based Pattern Discovery: The Example of Screening the WHO Global Drug Safety Database [ J ]. Statistical analysis and data mining, 2010,3:197-207.
[11] Caster O, Norén GN, Madigan D, et al. Large-Scale Regression-Based Pattern Discovery in International Adverse Drug Reaction Surveillance [C] . Paper presented at : Proceedings of the KDD Workshop on Mining Medical Data and KDD Cup 2008, Las Vegas, NV, USA.
[12] John Talbot, Patrick Waller. Stephen's detection of new adverse drug reactions ( fifth edition ) [M] . John Wiley & Sons Ltd 2007: 319-321.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.